Effects on Fatty Acid Metabolism of a New Powdered Human Milk Fortifier Containing Medium-Chain Triacylglycerols and Docosahexaenoic Acid in Preterm Infants
- PMID: 29843467
- PMCID: PMC6024374
- DOI: 10.3390/nu10060690
Effects on Fatty Acid Metabolism of a New Powdered Human Milk Fortifier Containing Medium-Chain Triacylglycerols and Docosahexaenoic Acid in Preterm Infants
Erratum in
-
Correction: Billeaud et al. "Effects on Fatty Acid Metabolism of a New Powdered Human Milk Fortifier Containing Medium-Chain Triacylglycerols and Docosahexaenoic Acid in Preterm Infants" Nutrients 2018, 10, 690.Nutrients. 2019 Mar 22;11(3):680. doi: 10.3390/nu11030680. Nutrients. 2019. PMID: 30909511 Free PMC article.
Abstract
Preterm infants require fortification of human milk (HM) with essential fatty acids (FA) to ensure adequate post-natal development. As part of a larger randomized controlled study, we investigated FA metabolism in a subset of 47 clinically stable preterm infants (birth weight ≤1500 g or gestational age ≤32 weeks). Infants were randomized to receive HM supplemented with either a new HM fortifier (nHMF; n = 26) containing 12.5 g medium-chain FA (MCFA), 958 mg linoleic acid (LA), 417 mg α-linolenic acid (ALA), and 157 mg docosahexaenoic acid (DHA) per 100 g of powder (in compliance with the latest guidelines) or a fat-free HMF (cHMF; n = 21). Plasma phospholipid (PL) and triacylglycerol (TAG), and red blood cell phosphatidylcholine (RBC-PC) and phosphatidylethanolamine (RBC-PE) FA profiles were assessed before and after 21 days of feeding. In the nHMF group, significantly increased levels of n-9 monounsaturated fatty acids were observed, formed most likely by elongation and desaturation of dietary saturated fatty acids present in HM. ALA fortification increased ALA assimilation into plasma TAG. Similarly, DHA fortification enriched the DHA content in RBC-PE, which, in this compartment, was not associated with lower arachidonic acid levels as observed in plasma TAG and phospholipids. RBC-PE, a reliable indicator of FA metabolism and accretion, was the most sensitive compartment in this study.
Keywords: arachidonic acid; docosahexaenoic acid; fatty acid metabolism; medium-chain fatty acids; preterm infants.
Conflict of interest statement
P.S., J.J., C.C.-H., L.A., N.P.H., and F.D. are employees of Nestlé SA. C.B., J.R., J.-C.P., and E.S. received research funding from Nestlé Nutrition. J.R., J.-C.P., and C.B. are consultants for Nestlé Nutrition. C.B.-V. and L.C. have no conflicts of interest to declare.
Figures

Comment in
-
Effects on Fatty Acid Metabolism of a New Powdered Human Milk Fortifier Containing Medium-Chain Triacylglycerols and Docosahexaenoic Acid in Preterm Infants.Nutrients. 2019 Jan 6;11(1):103. doi: 10.3390/nu11010103. Nutrients. 2019. PMID: 30621316 Free PMC article.
Similar articles
-
Docosahexaenoic acid in red blood cells of term infants receiving two levels of long-chain polyunsaturated fatty acids.J Pediatr Gastroenterol Nutr. 2006 Mar;42(3):287-92. doi: 10.1097/01.mpg.0000189366.91792.64. J Pediatr Gastroenterol Nutr. 2006. PMID: 16540798 Clinical Trial.
-
Effect of different levels of docosahexaenoic acid supply on fatty acid status and linoleic and α-linolenic acid conversion in preterm infants.J Pediatr Gastroenterol Nutr. 2012 Mar;54(3):353-63. doi: 10.1097/MPG.0b013e31823c3bfd. J Pediatr Gastroenterol Nutr. 2012. PMID: 22008957 Clinical Trial.
-
Growth and Nutritional Biomarkers of Preterm Infants Fed a New Powdered Human Milk Fortifier: A Randomized Trial.J Pediatr Gastroenterol Nutr. 2017 Oct;65(4):e83-e93. doi: 10.1097/MPG.0000000000001686. J Pediatr Gastroenterol Nutr. 2017. PMID: 28727654 Free PMC article. Clinical Trial.
-
Dietary PUFA for preterm and term infants: review of clinical studies.Crit Rev Food Sci Nutr. 2005;45(3):205-29. doi: 10.1080/10408690590956378. Crit Rev Food Sci Nutr. 2005. PMID: 16048149 Review.
-
Enteral and parenteral lipid requirements of preterm infants.World Rev Nutr Diet. 2014;110:82-98. doi: 10.1159/000358460. Epub 2014 Apr 11. World Rev Nutr Diet. 2014. PMID: 24751623 Review.
Cited by
-
Fortification of Human Milk for Preterm Infants: Update and Recommendations of the European Milk Bank Association (EMBA) Working Group on Human Milk Fortification.Front Pediatr. 2019 Mar 22;7:76. doi: 10.3389/fped.2019.00076. eCollection 2019. Front Pediatr. 2019. PMID: 30968003 Free PMC article. Review.
-
Comparative study of preterm infants fed new and existing human milk fortifiers showed favourable markers of gastrointestinal status.Acta Paediatr. 2020 Mar;109(3):527-533. doi: 10.1111/apa.14981. Epub 2019 Sep 30. Acta Paediatr. 2020. PMID: 31435957 Free PMC article. Clinical Trial.
-
Effects on Fatty Acid Metabolism of a New Powdered Human Milk Fortifier Containing Medium-Chain Triacylglycerols and Docosahexaenoic Acid in Preterm Infants.Nutrients. 2019 Jan 6;11(1):103. doi: 10.3390/nu11010103. Nutrients. 2019. PMID: 30621316 Free PMC article.
-
Role Medium-Chain Fatty Acids in the Lipid Metabolism of Infants.Front Nutr. 2022 Jun 9;9:804880. doi: 10.3389/fnut.2022.804880. eCollection 2022. Front Nutr. 2022. PMID: 35757267 Free PMC article. Review.
-
Correction: Billeaud et al. "Effects on Fatty Acid Metabolism of a New Powdered Human Milk Fortifier Containing Medium-Chain Triacylglycerols and Docosahexaenoic Acid in Preterm Infants" Nutrients 2018, 10, 690.Nutrients. 2019 Mar 22;11(3):680. doi: 10.3390/nu11030680. Nutrients. 2019. PMID: 30909511 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials